Vorapaxar

Administration

• Type: Antiplatelet
• Dosage Forms: Tab 2.08mg
• Routes of Administration: Oral
• Common Trade Names: Zontivity

Adult Dosing

Thrombotic event prevention

• 2.08 mg PO qd

Pediatric Dosing

Safety/efficacy not established in pediatric patients

Special Populations

Pregnancy Rating

• Caution advised during pregnancy
• Risk of increased maternal bleeding during delivery

Lactation risk

• Consider alternative while breastfeeding
• Possible drug excretion into milk based on drug properties

Renal Dosing

• Adult: No adjustment
• Pediatric: Unavailable

Hepatic Dosing

• Adult:
  • Severe Impairment: Avoid use
• Pediatric: Unavailable

Contraindications

• Allergy to class/drug
• Stroke or TIA hx
• Intracranial hemorrhage
• Active bleeding

Adverse Reactions

Serious

• Bleeding, severe
• Intracranial hemorrhage
• GI Bleeding
• Retinopathy

Common

• Bleeding, anemia
• Depression
• Rash

Pharmacology

• Half-life: 8 days w/ active metabolite
• Metabolism: Liver CYP450: 2J2, 3A4 substrate
• Excretion: Feces 58%, urine 25%

Mechanism of Action

• Antagonizes protease-activated receptor-1, inhibiting platelet aggregation induced by thrombin an thrombin receptor agonist peptide

See Also

• Antiplatelet medications
• Antiplatelet agent reversal